MONTGOMERY, ALA. (July 15, 2011) – Beasley, Allen, Crow, Methvin, Portis & Miles, P.C., attorney Chad Cook, who practices in the firm’s Mass Torts section, has been chosen to help direct litigation related to femur fractures caused by the osteoporosis medication Fosamax®. Chad is one of 11 lawyers selected to oversee the consolidated litigation as part of the Plaintiffs Steering Committee (PSC). The litigation, which involves hundreds of cases against Merck Sharp & Dohme, Corp., which manufactures Fosamax®, is consolidated under U.S. District Judge Garrett E. Brown, Jr., in the District of New Jersey.
“I am excited to serve on the Fosamax Femur Fracture PSC,” said Cook. “I look forward to working with a terrific group of attorneys in representing the victims who have suffered injuries as a result of taking Fosamax.”
Fosamax is a type of medication known as a bisphosphonate, prescribed for the treatment of bone loss and osteoporosis. The FDA reviewed data from an ongoing safety review of oral bisphosphonates to determine if use of the drug was related to an increased risk of thigh fractures, specifically low-energy femoral shaft and subtrochanteric fractures. In October of 2010 the FDA required all manufacturers of bisphosphonates to include in the warning section of their label a description of low-energy femoral shaft and subtrochanteric fractures that are associated with the use of drugs in this class.